Recent US Food and Drug Administration Warnings on Hepatitis B Reactivation With Immune-Suppressing and Anticancer Drugs: Just the Tip of the Iceberg?

Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti-CD20 agents ofatumumab or rituximab....

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Hepatology
Huvudupphovsmän: Di Bisceglie, Adrian M., Lok, Anna S., Martin, Paul, Terrault, Norah, Perrillo, Robert P., Hoofnagle, Jay H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497492/
https://ncbi.nlm.nih.gov/pubmed/25412906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27609
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk